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Background: Venous thromboembolism (VTE) causes morbidity and mortality in hospitalized patients, and
regulators and payors are encouraging the use of systems to prevent them. Here, we examine the effect of a
computerized clinical decision support (CDS) intervention implemented across a multi-hospital academic health
system on VTE prophylaxis and events.
Methods: The study included 223,062 inpatients admitted between April 2007 and May 2010, and used
administrative and clinical data. The intervention was integrated into a commercial electronic health record (EHR) in
an admission orderset used for all admissions. Three time periods were examined: baseline (period 1), and the time
after implementation of the first CDS intervention (period 2) and a second iteration (period 3). Providers were
prompted to accept or decline prophylaxis based on patient risk. Time series analyses examined the impact of the
intervention on VTE prophylaxis during time periods two and three compared to baseline, and a simple pre-post
design examined impact on VTE events and bleeds secondary to anticoagulation. VTE prophylaxis and events were
also examined in a prespecified surgical subset of our population meeting the public reporting criteria defined by
the Agency for Healthcare Research and Quality (AHRQ) Patient Safety Indicator (PSI).
Results: Unadjusted analyses suggested that “recommended”, “any”, and “pharmacologic” prophylaxis increased
from baseline to the last study period (27.1% to 51.9%, 56.7% to 78.1%, and 42.0% to 54.4% respectively; p < 0.01 for
all comparisons). Results were significant across all hospitals and the health system overall. Interrupted time series
analyses suggested that our intervention increased the use of “recommended” and “any” prophylaxis by 7.9% and
9.6% respectively from baseline to time period 2 (p < 0.01 for both comparisons); and 6.6% and 9.6% respectively
from baseline to the combined time periods 2 and 3 (p < 0.01 for both comparisons). There were no significant
changes in “pharmacologic” prophylaxis in the adjusted model. The overall percent of patients with VTE increased
from baseline to the last study period (2.0% to 2.2%; p = 0.03), but an analysis excluding patients with VTE “present
on admission” (POA) demonstrated no difference in events (1.3% to 1.3%; p = 0.80). Overall bleeds did not
significantly change. An analysis examining VTE prophylaxis and events in a surgical subset of patients defined by
the AHRQ PSI demonstrated increased “recommended”, “any”, and “pharmacologic” prophylaxis from baseline to
the last study period (32.3% to 60.0%, 62.8% to 85.7%, and 47.9% to 63.3% respectively; p < 0.01 for all comparisons)
as well as reduced VTE events (2.2% to 1.7%; p < 0.01).
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Conclusions: The CDS intervention was associated with an increase in “recommended” and “any” VTE prophylaxis
across the multi-hospital academic health system. The intervention was also associated with increased VTE rates in
the overall study population, but a subanalysis using only admissions with appropriate POA documentation
suggested no change in VTE rates, and a prespecified analysis of a surgical subset of our sample as defined by the
AHRQ PSI for public reporting purposes suggested reduced VTE. This intervention was created in a commonly used
commercial EHR and is scalable across institutions with similar systems.
Keywords: Electronic medical record, Electronic health record, Health information technology, Clinical decision
support, Venous thrombosis, Deep venous thrombosis, Quasi-experimental studyBackground
Venous thromboembolism (VTE) is an important cause
of morbidity and mortality in hospitalized patients. For
example, among greater than 7 million patients dis-
charged from 944 US acute care hospitals, postoperative
deep venous thrombosis (DVT) was the second most
common complication, second most common cause of
prolonged hospitalization, and the third most common
cause of excess mortality and charges [1].
Without VTE prophylaxis, the incidence of asymptom-
atic hospital-acquired DVT is as high as 20% among
medical patients, 40% among general surgical patients,
and 60% among orthopedic surgery patients [1]. Rates of
symptomatic DVT and pulmonary embolism (PE) with-
out pharmacologic prophylaxis are lower at approxi-
mately 1% and 1.2% respectively when measured during
the hospital stay for nonsurgical patients [2], and 2.8%
and 1.5% respectively at 35 days post-op for patients
undergoing major orthopedic surgery [3]. Pharmacologic
prophylaxis decreases symptomatic DVT and PE by ap-
proximately 25% and 30% respectively in nonsurgical
patients [2], and approximately 55% and 60% respect-
ively in major orthopedic surgery patients [3].
Given the impact of VTE on hospital inpatients, and
the effectiveness of prophylaxis at reducing VTE events,
hospital regulators and payors are beginning to
incentivize hospitals to implement systems changes to
prevent VTE. For example, in Fiscal Year 2009, Medi-
care stopped providing additional reimbursements for
DVT and PE following hip or knee replacement [4,5].
Many methods to improve VTE prophylaxis in the hos-
pital setting have been studied, including the use of
computerized clinical decision support (CDS) interven-
tions [6]. However, many of the CDS interventions stud-
ied were limited in that they either used noncommercial
homegrown electronic health records (EHR) [7–13],
pop-up alerts to remind providers when patients with
VTE risk factors were not on prophylaxis [7–11,13–16],
or targeted select populations [8,11,12] or individual
hospitals [17]. These limitations could impact the
generalizability of the studies’ findings across multi-
hospital systems, particularly given the ubiquitous natureof pop-up alerts and the associated alert fatigue [18],
challenges associated with translating the functionality
of a homegrown EHR into a commercial one, and obsta-
cles associated with implementing change across mul-
tiple institutions. In this study, we examine the effect on
VTE prophylaxis and event rates of integrating a CDS
intervention that does not involve pop-up alerts into a
commonly used commercial EHR serving all inpatients
in a multi-hospital academic health system.
Methods
Developing and implementing the CDS
The CDS intervention was developed, implemented and
tested in a quaternary care academic health system com-
prised of three acute care teaching hospitals: the 814 bed
flagship hospital (Hospital A), a 331 bed hospital best
known for its services in cardiology, ophthalmology,
orthopedics, family medicine, geriatrics and psychiatry
(Hospital B), and a 569 bed hospital best known for its
services in orthopedics, obstetrics and neurosurgery
(Hospital C). Overall, these three hospitals include 1,714
beds that are staffed by more than 4,000 attending physi-
cians, residents and fellows. The hospitals account for
approximately 80,000 admissions annually.
We created a CDS intervention that was linked to an
electronic admission order set in a commercial EHR
(Sunrise Clinical Manager 5.0, Allscripts, Chicago, IL)
used by these three hospitals. The intervention was
designed to improve VTE risk assessment and prophy-
laxis across these hospitals. Recommendations for
prophylaxis were based on locally adapted national
guidelines [1,19]. Key participants in the development
and implementation of the intervention were physicians,
nurses, quality specialists, pharmacists, informatics ana-
lysts, and anticoagulation experts.
Before launching the intervention across the health
system, pharmacists increased their stock of VTE
prophylaxis, and nurses increased the supply of mechan-
ical VTE prophylaxis on the wards. Nurses also imple-
mented a nursing education program about the
intervention and the availability of low molecular weight
heparin (LMWH) as a VTE prophylaxis option. In
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tion was distributed to all faculty and staff. Lastly, a
point-of-use educational video was developed and imple-
mented to educate ordering providers about the
intervention.
The first iteration was launched at Hospital A and
Hospital B on 4/7/08, and at Hospital C on 4/8/08. This
version required the admitting provider to accept or de-
cline VTE prophylaxis based on patient risk. Providers
were expected to order prophylaxis unless their patients
were low risk as defined by the absence of eleven
listed risk factors (1. age ≥40, 2. recent surgery
lasting ≥ 45 minutes, 3. history of venous thrombo-
embolism, 4. history of hypercoagulability, 5. history of
cancer, 6. obesity (BMI ≥ 30), 7. ongoing estrogen or
anti-androgen use, 8. history of varicose veins, 9.
reduced mobility, 10. weakness or paralysis of ≥ one
limb, 11. expected length of stay ≥ 3 days). Because it
was rare for a patient to have none of the eleven listed
risk factors, we did not ask providers to check off risk
factors as part of the ordering process, nor did the CDS
auto-populate risk factors based on the medical record.
If prophylaxis was declined, a reason had to be specified
using a drop down menu, which included a set of pre-
defined reasons (e.g. patient has none of the listed risk
factors, patient is on therapeutic anticoagulation) as well
as an option to insert free text. If prophylaxis was
accepted, a list of contraindications to pharmacologic
prophylaxis was displayed and included: active or recent
bleeding, known bleeding disorder or coagulopathy (INR
2 or greater), patient on therapeutic anticoagulation with
heparin or warfarin, platelet count less than 50,000; for
heparins, history of heparin-induced thrombocytopenia
or allergy to heparin; for low molecular weight heparins,
creatinine clearance less than 30 mL/min or epidural
catheter; and for warfarin, pregnancy. The user could
then enter the admission order and proceed to a separ-
ate VTE prophylaxis order set that would provide guid-
ance to the most appropriate prophylaxis based on the
clinical service. A second iteration of the CDS, launched
across the health system on 9/15/09, combined the VTE
risk assessment and prophylaxis order grid into one
intervention embedded in the electronic admission
orderset. Providers were then confronted with three
options instead of two: 1) pharmacologic prophylaxis;
2) mechanical prophylaxis only; or 3) no prophylaxis.
The last two options required a reason to be specified.
When a user selected the “pharmacologic prophylaxis”
option, the order grid appeared and would automatic-
ally populate based on the service selected by the user
(Figure 1A and B). The second iteration also included
an updated list of risk factors, pharmacologic contrain-
dications, and pre-defined reasons to decline prophy-
laxis. Both versions of the intervention included logicto prevent two anticoagulants from being ordered at
once, and a glomerular filtration rate (GFR) calculator
to prevent the use of LMWH in those with a creatinine
clearance less than 30 cc/min.
Study subjects
The retrospective study was approved by the University
of Pennsylvania Institutional Review Board with a
HIPAA waiver. Study subjects included all adults admit-
ted to an acute care inpatient service at our academic
health system. Those in our original dataset without a
listed discharging service were excluded. The first study
period included admissions in the 12 months prior to
the first CDS intervention; the second period included
admissions between the first and second versions of the
CDS intervention; the third period included admissions
in the eight months following the implementation of the
revised CDS intervention (9/15/09-5/31/10 for Hospital
A, Hospital B, and Hospital C).
Data sources and measures
Clinical data was retrieved from the inpatient EHR, and
administrative data was retrieved from Horizon Per-
formance Manager (HPM), which included profession-
ally coded data from the medical record.
Measures included descriptive characteristics of
patients (age, gender, race, insurance status, length of
stay, weight, creatinine clearance as estimated by the
Cockcroft-Gault equation, discharging unit and hospital,
primary and secondary discharge diagnostic codes, and
severity of illness as measured by diagnostic related
group [DRG] weight), CDS utilization measures (includ-
ing provider response to the CDS intervention [i.e., a
“yes” versus “no” response to the question of whether or
not the provider would order VTE prophylaxis] as well
as selected reasons for declining prophylaxis), and VTE
process and outcome measures. Inpatient services were
categorized into “medicine” services (neurology, allergy,
cardiology, endocrinology/diabetes, family medicine,
gastroenterology, general internal medicine, geriatrics,
hematology/oncology, hospitalists, infectious diseases,
neurology, pulmonary, renal/metabolic and rheumatol-
ogy), “orthopedic/trauma” services, and the “other sur-
gery” services (anesthesia, cardiac surgery, colorectal
surgery, obstetrics, gynecological oncology, gastrointes-
tinal surgery, maternal fetal medicine, neurosurgery, oto-
laryngology, plastic surgery, general surgery, surgical
oncology, thoracic surgery, transplant surgery, urology,
oral/maxillofacial, and vascular surgery). VTE process
measures included percent of patients on recommended
prophylaxis (per our guideline), any prophylaxis (i.e.,
pharmacologic or mechanical), and pharmacologic
prophylaxis (i.e., unfractionated heparin, LMWH, or
warfarin). Recommended prophylaxis was defined as
A 
B 
Figure 1 Screenshots of clinical decision support intervention. A. Admission order set containing VTE prophylaxis risk assessment; B. VTE
prophylaxis order grid.
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daily or warfarin for the orthopedics/trauma services;
and unfractionated heparin (UFH) 5,000U thrice daily,
enoxaparin 40 mg once daily, or dalteparin 5000U once
daily for the medicine services and other surgery ser-
vices. Any prophylaxis was defined as any pharmacologic
prophylaxis or mechanical prophylaxis (i.e. intermittent
pneumatic compression devices). Any pharmacologicprophylaxis was defined as any standard prophylactic
UFH or LMWH dose, or any warfarin dose for the
orthopedics/trauma services. Unless otherwise stated,
patients were judged to receive pharmacologic prophy-
laxis if they were administered at least one ordered dose.
Mechanical prophylaxis was defined by order only. Clin-
ical outcome measures included VTE and bleeding
events during hospitalization. VTE events were defined
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diagnosis of PE or DVT as defined by the International
Classification of Diseases Version 9 (ICD9) codes listed
in the Agency for Healthcare Research and Quality
(AHRQ) Patient Safety Indicators (PSI) Technical Speci-
fications Guide under PSI 12 [20]. Discharges that
included the PE or DVT codes as primary discharge
diagnoses were excluded. The AHRQ definition of VTE
was applied to the overall study population, as well as a
prespecified surgical subset of our study population who
met the AHRQ PSI criteria for public reporting of VTE
events [20]. A subanalysis was performed excluding
patients with VTE codes listed as “present on admission”
(POA). POA data was only available for hospitalizations
after 10/1/07 at Hospital A, 11/7/07 at Hospital C, and
4/1/08 at Hospital B. Bleeding was defined as any one of
a set of secondary discharge diagnosis codes related to
bleeding [21] combined with any one of a set of E codes
representing medical or drug errors (E858.1, E858.2,
E858.8, E858.9, E876.8, E876.9, E934.2, E934.3, E934.8,
E947.8, E947.9, E980.4, E980.5).
Data analysis
Unadjusted analyses using chi-square tests for dichotom-
ous variables and t tests for continuous variables com-
pared demographics and the proportion of VTE process
and outcome measures across the three time periods.
Unadjusted analyses using chi-square tests were also
used to compare over our two follow-up periods the
proportion of providers who ordered prophylaxis when
they indicated in the CDS that they would do so, as well
as the proportion of providers who did not order
prophylaxis when they indicated in the CDS that they
would not do so. In addition, proportions were calcu-
lated for the reasons noted or selected for declining
prophylaxis.
Adjusted analyses using interrupted time series models
estimated the impact of the original and revised CDS
interventions on administration of VTE prophylaxis.
These analyses were employed using the SAS/ETS pro-
cedure PROC AUTOREG with the CHOW option (SAS,
1999). This type of analysis allowed us to measure the
impact of the CDS interventions while adjusting for the
serial correlation among hospital level data collected se-
quentially in time as well as potential unmeasured con-
founders, such as other quality interventions that could
have impacted VTE prophylaxis [22].
Results
The study included 223,062 inpatients across our three
hospitals in the study time period (between April 2007
and May 2010), and excluded 1546 encounters (0.70% of
the total encounters in our dataset) who did not have a
discharge service listed. The baseline characteristics ofthe patient populations across our three time periods
were clinically similar (Table 1).
In our unadjusted analyses, “recommended” prophy-
laxis significantly increased across the three study peri-
ods across all hospitals and services (27.1% vs. 43.0% vs.
51.9%; p < 0.01). (Table 2 and Figure 2A) “Other surgical
services” had the greatest increase overall from 19.8% to
38.5% to 48.2% (p < 0.01). The orthopedics/trauma ser-
vices had the lowest rate of increase overall, from 44.4%
to 46.4% to 48.8% (p < 0.01), but had the highest rate of
“recommended prophylaxis” before the CDS interven-
tions. The administration of “any” prophylaxis increased
as well across all hospitals and services (56.7% vs. 74.7%
vs. 78.1%; p < 0.01) (Table 3 and Figure 2B). The ortho-
pedics/trauma services had the highest baseline rate of
“any” prophylaxis at 65.9%, which increased to 91.5%
and 97.0% (p < 0.01) after the first and second iterations
of the CDS interventions respectively. “Pharmacologic”
prophylaxis also increased across each of our hospitals
and the health system overall (42.0% vs. 47.6% vs. 54.4%;
p < 0.01) (Table 4). “Other surgical services” had the
greatest increase overall from 33.3% to 42.1% to 49.2%
(p < 0.01).
Table 5A and B contain the adjusted estimates from
the interrupted time series regression models of the
effects of the two versions of the CDS intervention on
mean monthly percentage of patients receiving “recom-
mended” and “any” prophylaxis by individual hospital
and hospital system. The estimates suggest the interven-
tion increased the use of “recommended” and “any”
prophylaxis at all three hospitals when comparing the
baseline time period 1 with time period 2, and when
comparing the baseline time period 1 with the combined
intervention periods 2 and 3 (p-values < 0.01). The differ-
ences between the intervention periods 2 and 3 were not
statistically significant. Our adjusted estimates suggest
that the CDS intervention did not significantly increase
the use of “pharmacologic” prophylaxis overall or at the
level of the hospital across any of the time periods exam-
ined in the model.
To better understand the changes in pharmacologic
and mechanical prophylaxis occurring as a result of the
CDS interventions, we examined the change in admin-
istration of specific prophylaxis regimens by service
and hospital. In general, there was a marked reduction
in “no prophylaxis” for all services, most prominently
orthopedics/trauma, which decreased its overall “no
prophylaxis” rate from 34.1% to 8.5% to 3.0% across
the three study periods (p < 0.01). The greatest increase
in prophylaxis on the orthopedics/trauma services was
mechanical prophylaxis, which increased overall from
14.5% to 35.3% to 37.0% (p < 0.01) across the three
study periods. There were minor increases in recom-
mended pharmacologic prophylaxis on the orthopedics/
Table 1 Descriptive statistics of patient population across study time periods
Variable Period 1 Period 2 Period 3 P value
Age (years) Mean (SD) 53.6 (19.1) 53.6 (19.1) 54.0 (18.9) <0.01
Sex Female 40,333 (57.4%) 58,506 (57.1%) 28,799 (57.2%) 0.56
Race White 38,317 (54.5%) 56,095 (54.8%) 27,039 (53.7%) <0.01
Other 31,547 (44.9%) 45,984 (44.9%) 23,109 (45.9%)
Unknown 419 (0.6%) 329 (0.3%) 223 (0.4%)
Health Insurance Self Pay 841 (1.2%) 1,258 (1.2%) 501 (1.0%) <0.01
Insured 65,246 (92.8%) 99,895 (97.5%) 49,307 (97.9%)
Unknown 4,196 (6.0%) 1,255 (1.2%) 563 (1.1%)
Weight (kg) Mean (SD) 82.3 (24.0) 82.8 (24.1) 82.8 (24.1) <0.01
CrCl <30 Yes 5,159 (9.7%) 7,547 (9.9%) 3,828 (8.8%) <0.01
No 47,855 (90.3%) 68,743 (90.1%) 39,513 (91.2%)
Length of Stay (days) Mean (SD) 5.2 (7.7) 5.1 (7.6) 5.2 (7.0) <0.01
DRG Weight Mean (SD) 1.7 (1.9) 1.7 (1.9) 1.7 (2.0) <0.01
Discharging Unit Medicine 2,488 (46.2%) 47,973 (46.8%) 24,373 (48.4%) <0.01
Ortho/Trauma 7,657 (10.9%) 11,506 (11.2%) 5,825 (11.6%)










Second Osteoarthritis 2,327 (3.6%) Osteoarthritis 3,505 (3.5%) Osteoarthritis 1,805 (3.7%)
Third CAD 2,104 (3.3%) CAD 3,342 (3.4%) Dysrhythmia 1,676 (3.5%)
Fourth CHF 1,971 (3.0%) Dysrhythmia 3,321 (3.4%) CHF 1,460 (3.0%)
Fifth Dysrhythmia 1,940 (3.0%) Birth complications 2,935 (3.0%) CAD 1,419 (2.9%)
Abbreviations: CAD, coronary artery disease; CHF, congestive heart failure; CrCl, creatinine clearance; DRG, diagnosis-related group; SD, standard deviation.
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priate LMWH usage from 15.7% to 19.1% to 18.8%
(p < 0.01). On the medicine services, there were signifi-
cant changes in the types of pharmacologic prophylaxisTable 2 Change in administration of recommended prophyla
periods
Hospital Discharge service Period 1
Hospital A Medicine 5,614 (36.7%)
Ortho/Trauma 659 (32.1%)
Other Surgery 4,372 (25.1%)
All 10,645 (30.6%)
Hospital B Medicine 3,460 (35.6%)
Ortho/Trauma 690 (34.5%)
Other Surgery 584 (30.8%)
All 4,734 (34.8%)
Hospital C Medicine 581 (7.8%)
Ortho/Trauma 2,052 (57.0%)
Other Surgery 1,005 (9.3%)
All 3,638 (16.6%)
Overall Medicine 9,655 (29.7%)
Ortho/Trauma 3,401 (44.4%)
Other Surgery 5,961 (19.8%)
All 19,017 (27.1%)ordered by providers. The use of twice daily UFH was
reduced from 17.5% to 3.6% to 1.6% (p < 0.01) across
the three time periods in favor of recommended
pharmacologic prophylaxis regimens including thricexis by hospital and service across the three study time
Period 2 Period 3 P-value
10,623 (46.2%) 6,491 (54.6%) <0.01
1,215 (35.2%) 746 (40.1%) <0.01
10,856 (42.9%) 6,096 (52.5%) <0.01
22,694 (43.9%) 13,333 (52.5%) <0.01
6,648 (45.7%) 3,661 (53.2%) <0.01
1,323 (42.9%) 709 (44.1%) <0.01
1,393 (50.4%) 771 (58.6%) <0.01
9,364 (45.9%) 5,141 (52.4%) <0.01
4,897 (47.0%) 3,411 (61.0%) <0.01
2,797 (56.3%) 1,390 (58.9%) 0.10
4,265 (28.7%) 2,847 (39.3%) <0.01
11,959 (39.5%) 7,648 (50.3%) <0.01
22,168 (46.2%) 13,563 (55.6%) <0.01
5,335 (46.4%) 2,845 (48.8%) <0.01
16,514 (38.5%) 9,714 (48.2%) <0.01
44,017 (43.0%) 26,122 (51.9%) <0.01
A 
B 
Figure 2 Proportion of patients receiving VTE prophylaxis by month. A. Recommended VTE prophylaxis; B. Any VTE prophylaxis.
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p < 0.01) and LMWH (increased from 0.4% to 7.8% to
4.5%, p < 0.01). Increases in thrice daily UFH were most
pronounced at Hospital C (increasing from 6.6% to
38.9% to 58.0%, p < 0.01). The “other surgical” services
also reduced their rates of “no prophylaxis” from 46.1%
to 22.8% to 20.3% (p < 0.01) in favor of sharp increases
in the use of thrice daily UFH (from 19.5% to 37.9% to
47.5%, p < 0.01). Unlike the medicine services, the “other
surgical” services did not have a clinically significantincrease in the amount of LMWH administered (0.5% to
0.7% to 0.7%, p < 0.01).
There was a significant increase in VTE in the overall
study population (2.0% vs. 2.1% vs. 2.2%; p = 0.02); how-
ever, subanalyses excluding VTE that were “present on
admission” suggested no difference in VTE events across
the three time periods (1.3% vs. 1.3% vs. 1.3%; p = 0.80).
The number of patients with documented bleeds related
to anticoagulation was low at 0.1% across all three time
periods.
Table 3 Change in administration of any prophylaxis by hospital and service across the three study time periods
Hospital Discharge service Period 1 Period 2 Period 3 P-value
Hospital A Medicine 8,021 (52.4%) 15,405 (67.0%) 8,655 (72.8%) <0.01
Ortho/Trauma 1,275 (62.0%) 3,035 (87.9%) 1,808 (97.2%) <0.01
Other Surgery 9,344 (53.7%) 20,273 (80.2%) 9,726 (83.7%) <0.01
All 18,640 (53.6%) 38,713 (74.8%) 20,189 (79.6%) <0.01
Hospital B Medicine 4,937 (50.8%) 9,306 (64.0%) 4,510 (65.5%) <0.01
Ortho/Trauma 826 (41.3%) 2,810 (91.0%) 1,548 (96.4%) <0.01
Other Surgery 981 (51.7%) 1,989 (71.9%) 1,088 (82.7%) <0.01
All 6,744 (49.6%) 14,105 (69.1%) 7,146 (72.9%) <0.01
Hospital C Medicine 5,553 (74.3%) 8,123 (77.9%) 4,445 (79.4%) <0.01
Ortho/Trauma 2,947 (81.8%) 4,682 (94.3%) 2,294 (97.3%) <0.01
Other Surgery 5,932 (54.8%) 10,878 (73.1%) 5,257 (72.7%) <0.01
All 14,432 (65.9%) 23,683 (78.3%) 11,996 (79.0%) <0.01
Overall Medicine 18,511 (57.0%) 32,834 (68.4%) 17,610 (72.3%) <0.01
Ortho/Trauma 5,048 (65.9%) 10,527 (91.5%) 5,650 (97.0%) <0.01
Other Surgery 16,257 (53.9%) 33,140 (77.2%) 16,071 (79.7%) <0.01
All 39,816 (56.7%) 76,501 (74.7%) 39,331 (78.1%) <0.01
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cal subset of patients defined by the AHRQ PSI used for
public reporting demonstrated increased “recom-
mended,” “any,” and “pharmacologic” prophylaxis from
baseline to the last study period (32.3% vs. 50.7% vs.
60.0%, 62.8% vs. 82.0% vs. 85.7%, and 47.9% vs. 56.3% vs.
63.3%, respectively; p < 0.01 for all comparisons) as well
as a significant reduction in DVT and overall VTE
events, but a significant increase in PE (Table 6).
When we examined the type of prophylaxis adminis-
tered stratified by how the provider initially respondedTable 4 Change in administration of pharmacologic prophyla
periods
Hospital Discharge service Period 1
Hospital A Medicine 6,753 (44.1%)
Ortho/Trauma 1,121 (54.5%)
Other Surgery 6,623 (38.0%)
All 14,497 (41.7%)
Hospital B Medicine 4,455 (45.9%)
Ortho/Trauma 710 (35.5%)
Other Surgery 911 (48.0%)
All 6,076 (44.6%)
Hospital C Medicine 4,330 (57.9%)
Ortho/Trauma 2,103 (58.4%)
Other Surgery 2,498 (23.1%)
All 8,931 (40.8%)
Overall Medicine 15,538 (47.8%)
Ortho/Trauma 3,934 (51.4%)
Other Surgery 10,032 (33.3%)
All 29,504 (42.0%)to the CDS intervention (i.e., a “yes” versus “no” re-
sponse to the question of whether or not the provider
would order VTE prophylaxis), we found that most pro-
viders who indicated they would order prophylaxis did
order it, and that proportion increased over our two
follow-up periods, from 89.0% to 93.8% in periods 2 and
3, respectively (p < 0.01). Those who said they wouldn't
order prophylaxis often did not (63.7% ordered no
prophylaxis in period 2 vs. 74.1% in period 3, p < 0.01).
The most commonly stated reasons for not ordering
prophylaxis were that the patient 1) had no risk factorsxis by hospital and service across the three study time
Period 2 Period 3 P-value
10,977 (47.7%) 6,662 (56.0%) <0.01
2,207 (63.9%) 1,301 (69.9%) <0.01
11,638 (46.0%) 6,162 (53.0%) <0.01
24,822 (48.0%) 14,125 (55.7%) <0.01
7,136 (49.0%) 3,792 (55.1%) <0.01
1,355 (43.9%) 730 (45.5%) <0.01
1,563 (56.5%) 800 (60.8%) <0.01
10,054 (49.3%) 5,322 (54.3%) <0.01
6,067 (58.2%) 3,538 (63.2%) <0.01
2,902 (58.4%) 1,463 (62.0%) <0.01
4,862 (32.7%) 2,968 (41.0%) <0.01
13,831 (45.7%) 7,969 (52.5%) <0.01
24,180 (50.4%) 13,992 (57.4%) <0.01
6,464 (56.2%) 3,494 (60.0%) <0.01
18,063 (42.1%) 9,930 (49.2%) <0.01
48,707 (47.6%) 27,416 (54.4%) <0.01
Table 5 Estimated increase in VTE prophylaxis use secondary to the clinical decision support
A. From time period 1 to time period 2
Hospital A Hospital B Hospital C Overall
Baseline Increase Baseline Increase Baseline Increase Baseline Increase
Recommended (%) 31.5 3.2 (p=0.09) 34.5 6.7 (p<.01) 16.4 13.9 (p<.01) 27.1 7.9 (p<.01)
Any Prophylaxis (%) 55.0 10.3 (p<.01) 49.5 13.0 (p<.01) 65.5 6.6 (p<.01) 57.2 9.6 (p<.01)
B. From time period 1 to time periods 2 and 3
Hospital A Hospital B Hospital C Overall
Baseline Increase Baseline Increase Baseline Increase Baseline Increase
Recommended (%) 30.9 3.7 (p=0.03) 34.5 5.4 (p=0.01) 16.4 13.6 (p<.01) 27.2 6.6 (p<.01)
Any Prophylaxis (%) 55.3 10.4 (p<.01) 49.5 14.6 (p<.01) 65.5 7.2 (p<.01) 57.5 9.6 (p<.01)
Abbreviations: VTE, venous thromboembolism.
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was peri-procedure (4%), or 4) was a bleeding risk (2%).Discussion
The increases in “recommended” and “any” VTE
prophylaxis attributable to the CDS intervention evalu-
ated in our study per our interrupted time series ana-
lyses are comparable to the one randomized controlled
trial that evaluated a CDS intervention to improve VTE
prophylaxis [10]. In addition, our revision to the CDS
intervention where we linked the risk assessment to the
prophylaxis order set grid had the intended effect of im-
proving the concordance between the users’ risk assess-
ments (i.e. what they said they would order) and the
prophylaxis actually ordered.Table 6 Change in VTE as defined by AHRQ PSI by
hospital across the study time periods
Period 1 Period 2 Period 3 P Value
Hospital A
DVT 2.27 (%) 2.27 (%) 1.56 (%) <0.01
PE 0.68 (%) 0.71 (%) 0.80 (%) 0.34
DVT/PE 2.82 (%) 2.80 (%) 2.18 (%) <0.01
Hospital B
DVT 1.05 (%) 0.88 (%) 0.44 (%) <0.01
PE 0.42 (%) 0.41 (%) 0.71 (%) <0.01
DVT/PE 1.42 (%) 1.20 (%) 1.09 (%) 0.06
Hospital C
DVT 1.64 (%) 1.67 (%) 1.08 (%) <0.01
PE 0.29 (%) 0.27 (%) 0.62 (%) <0.01
DVT/PE 1.83 (%) 1.86 (%) 1.48 (%) 0.10
Overall
DVT 1.77 (%) 1.75 (%) 1.15 (%) <0.01
PE 0.52 (%) 0.53 (%) 0.74 (%) <0.01
DVT/PE 2.18 (%) 2.15 (%) 1.73 (%) <0.01
Abbreviations: AHRQ PSI, Agency for Healthcare Research and Quality Patient
Safety Indicator; DVT, deep venous thrombosis; PE, pulmonary embolism; VTE,
venous thromboembolism.Advantages to the approach we employed are several.
First, we were able to avoid the use of pop-up alerts and
the risk for subsequent alert fatigue [18]. Second, we
were able to create our order set within a commercial
EHR used by more than 300 academic and community
healthcare institutions in and outside the U.S.; thus, our
intervention can be utilized by many other institutions
either using the same or a similar EHR. Third, we were
able to reach all hospitalized populations across multiple
hospitals in an academic health care system, instead of
select populations [8,11,12] or a single hospital [17] as
investigated in many other studies.
Despite our increase in “recommended” and “any” VTE
prophylaxis, the VTE event rates across our overall study
population increased (2.0% to 2.1% to 2.2%; p = 0.02).
There are a number of potential explanations. First,
improvements in coding may have increased the number
of VTE events captured. To understand the impact of
coding, we performed a subanalysis where we excluded
patients with VTE codes listed as POA; this resulted in no
significant difference in VTE rates across our study peri-
ods (1.3% vs. 1.3% vs. 1.3%; p = 0.80), suggesting that
increased coding of VTE diagnoses that were actually
POA may have resulted in a seeming increase in overall
VTE rates across our study periods. Second, there may
have been an increase in the VTE risk of our study popu-
lation over time. Although Table 1 indicated few clinically
significant changes, a post hoc analysis of the proportion
of our patients receiving peripherally inserted central
catheters or midlines during their hospital stay suggested
an increase in the use of such lines (6.9% vs. 7.1% vs. 8.2%
for study periods 1, 2 and 3 respectively; p < 0.01). This
could increase the risk of line-associated (LA) VTE, and is
an important VTE risk factor as routine prophylaxis has
not been consistently shown to be effective in reducing
the rate of LA VTE [23–27]. Unfortunately, codes differ-
entiating LA VTE from other VTE were not used in our
health system until the end of our study period. Third, our
measure of VTE prophylaxis was defined by the order
selected at time of admission for mechanical prophylaxis,
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pharmacologic prophylaxis. Thus, if mechanical prophy-
laxis was not routinely applied to patients, or if subse-
quent doses of pharmacologic prophylaxis were routinely
missed or not administered, then we wouldn’t expect to
see an impact of the intervention on VTE rates. Finally,
our hospital system switched LMWH products from
enoxaparin to dalteparin in December 2009. It is unclear
what impact this switch may have had on VTE rates, al-
though limited evidence suggests no differences between
the two products [28].
Despite the lack of improvement in VTE rates over time
in our overall study population, the analysis of a prespeci-
fied surgical subset of our sample as defined by the AHRQ
PSI for public reporting purposes [20] demonstrated a sta-
tistically significant reduction in DVT and overall VTE
events. Increased awareness of and emphasis on VTE
prophylaxis in this subpopulation as a result of the AHRQ
PSI metric may have caused the greater improvements in
VTE prophylaxis demonstrated in this subpopulation. Spe-
cifically, those services described as the “other surgical ser-
vices” in our study had the greatest increases overall in
both recommended prophylaxis (with an approximate ab-
solute increase of 30% over the study period) and pharma-
cologic prophylaxis (with an approximate absolute increase
of 20% over the study period). Such large increases in
prophylaxis may have resulted in the reduction in VTE
events demonstrated in this subpopulation. The findings
from this subpopulation also suggest that our intervention
may have more impact in populations at higher risk of
VTE (such as the surgical population defined by the AHRQ
measure), the effect of which is blunted when the entire
hospital population is analyzed.
The increase in PE demonstrated in the subanalysis of
the AHRQ PSI surgical population is more challenging
to explain. To our knowledge, there were no changes in
our patient population over time that would have
increased their risk of PE without increasing their risk of
DVT. Moreover, there were no changes in documenta-
tion codes for PE during the study period. It is possible
that increased national awareness of VTE may have
increased providers’ clinical suspicion for PE out of pro-
portion to their clinical suspicion for DVT, and this may
have resulted in increased testing for and diagnosis of
PE. In addition, recent publications have suggested that
the improved sensitivities of new CT technology and
protocols have resulted in the diagnosis of PEs pre-
viously undetected and unsuspected [29–31]. Such im-
provements may have contributed to the increased
incidence of PE demonstrated in the US in the last two
decades [29,30], as well as the increased incidence of PE
demonstrated across the three years of this study.
When accounting for VTE “present on admission”,
our overall health system VTE rate of 1.3% is reasonablyconsistent with those we would expect in an inpatient
population treated with VTE prophylaxis. Studies sug-
gest that rates can be as low as 0.8% for symptomatic
DVT and 0.8% for PE in nonsurgical patients [2], and as
low as 1.3% for symptomatic DVT and 0.6% for PE (for a
total VTE rate of 1.8%) in patients undergoing major
orthopedic surgery [3].
Our study has limitations. First, our simple pre-post
design does not fully account for secular changes that
may result in improvements in VTE prophylaxis and
reductions in VTE events, such as greater awareness of
the importance of VTE prophylaxis among providers.
However, our use of multiple time points before and
after the intervention, including modeling to adjust for
secular trends in the data, allow us to estimate with
more certainty the change in VTE prophylaxis directly
attributable to the intervention. Second, our measure of
VTE events and bleeding are based on administrative
data and are dependent on appropriate documentation
and coding. However, a prior study suggests that admin-
istrative data can have reasonable sensitivity for VTE,
with sensitivities for DVT and PE of 87% and 78% re-
spectively [32]. Another study reported reasonable test
characteristics for the bleeding codes we used, with 93%
sensitivity and 88% specificity for “any” bleeding, and
94% sensitivity and 83% specificity for “major” bleeding
[21]. However, this suggests that some bleeds we attribu-
ted to VTE prophylaxis were actually due to other
causes, and that some bleeds due to VTE prophylaxis
were missed by our analysis. In addition, our definition
of hospital-acquired VTE was limited by the lack of
documentation in our records regarding VTE “present
on admission” for the first six months of the baseline
period of our study for Hospital A and Hospital C, and
for the entire baseline period of our study for Hospital
B. Thus, our primary analyses could not discriminate as
well between VTE “present on admission” and those
acquired during the hospital stay. This along with in-
creased coding for VTE in general may have accounted
for the seeming increases in our VTE events over time
as described above, increases which were NOT demon-
strated in our subanalysis using only admissions with ap-
propriate POA documentation. Third, our measure of
why providers declined VTE prophylaxis is limited by
provider self report. Fourth, our study did not examine
the effect of our CDS intervention on VTE events after
hospital discharge, where many such events may occur.
Lastly, our CDS intervention was based on a national
guideline [1] that has since been updated [3,33,34].
Conclusions
Our analysis demonstrated significant increases in VTE
prophylaxis that were associated with a CDS interven-
tion integrated into an electronic admission order across
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tion was also associated with increased VTE rates in the
overall study population, but a subanalysis using only
admissions with appropriate POA documentation sug-
gested no change in VTE rates, and a prespecified ana-
lysis of a surgical subset of our sample as defined by the
AHRQ PSI for public reporting purposes suggested
reduced VTE. This CDS was created in a commonly
used commercial EHR and is thus scalable across other
institutions with similar systems.
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